ABSTRACT
Macrophages are central to inflammation resolution, an active process aimed at restoring tissue homeostasis following an inflammatory response. Here, the effects of db-cAMP on macrophage phenotype and function were investigated. Injection of db-cAMP into the pleural cavity of mice induced monocytes recruitment in a manner dependent on PKA and CCR2/CCL2 pathways. Furthermore, db-cAMP promoted reprogramming of bone-marrow-derived macrophages to a M2 phenotype as seen by increased Arg-1/CD206/Ym-1 expression and IL-10 levels (M2 markers). Db-cAMP also showed a synergistic effect with IL-4 in inducing STAT-3 phosphorylation and Arg-1 expression. Importantly, db-cAMP prevented IFN-γ/LPS-induced macrophage polarization to M1-like as shown by increased Arg-1 associated to lower levels of M1 cytokines (TNF-α/IL-6) and p-STAT1. In vivo, db-cAMP reduced the number of M1 macrophages induced by LPS injection without changes in M2 and Mres numbers. Moreover, db-cAMP enhanced efferocytosis of apoptotic neutrophils in a PKA-dependent manner and increased the expression of Annexin A1 and CD36, two molecules associated with efferocytosis. Finally, inhibition of endogenous PKA during LPS-induced pleurisy impaired the physiological resolution of inflammation. Taken together, the results suggest that cAMP is involved in the major functions of macrophages, such as nonphlogistic recruitment, reprogramming and efferocytosis, all key processes for inflammation resolution.
Subject(s)
Cellular Reprogramming , Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclic AMP/metabolism , Macrophages/metabolism , Phagocytosis , Animals , Annexin A1/metabolism , Apoptosis/drug effects , Arginase/metabolism , Bucladesine/pharmacology , CD36 Antigens/metabolism , Cell Polarity/drug effects , Cellular Reprogramming/drug effects , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Inflammation/pathology , Interleukin-4/metabolism , Isoquinolines/pharmacology , Lipopolysaccharides , Macrophages/drug effects , Male , Mice, Inbred BALB C , Models, Biological , Monocytes/drug effects , Monocytes/metabolism , Neutrophils/drug effects , Neutrophils/metabolism , Neutrophils/pathology , Phagocytosis/drug effects , Phenotype , Phosphorylation/drug effects , Pleural Cavity/metabolism , Receptors, CCR2/metabolism , STAT3 Transcription Factor/metabolism , Sulfonamides/pharmacology , Time FactorsABSTRACT
Campomanesia xanthocarpa (Myrtaceae) is used in Brazilian traditional medicine against fever, diabetes, hypercholesteremic, obesity, and urinary diseases. In the present study, the compounds 2',6'-dihydroxy-3'-methyl-4'-metoxychalcone and 2',4'-dihydroxy-3',5'-dimethyl-6'-methoxychalcone were identified for the first time in leaves of the C. xanthocarpa. These compounds and the hydroethanolic extract (HECX) significantly inhibited paw edema and reduced both leukocyte migration and the leakage of protein into the pleural cavity. No toxicity was detected by HECX in an acute toxicity test.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Chalcones/pharmacology , Myrtaceae/chemistry , Animals , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/therapeutic use , Brazil , Cell Movement/drug effects , Chalcones/isolation & purification , Chalcones/therapeutic use , Chalcones/toxicity , Edema/drug therapy , Leukocytes/cytology , Medicine, Traditional/methods , Mice , Plant Extracts/therapeutic use , Plant Leaves/chemistry , Pleural Cavity/metabolism , Proteins/metabolismABSTRACT
Chemokines are essential mediators of leukocyte movement in vivo. In vitro assays of leukocyte migration cannot mimic the complex interactions with other cell types and matrix needed for cells to extravasate and migrate into tissues. Therefore, in vivo strategies to study the effects and potential relevance of chemokines for the migration of particular leukocyte subsets are necessary. Here, we describe methods to study the effects and endogenous role of chemokine in mice. Advantages and pitfalls of particular models are discussed and we focus on description in model's joint and pleural cavity inflammation and the effects and relevance of CXCR2 and CCR2 ligands on cell migration.
Subject(s)
Arthritis, Experimental/metabolism , Chemokines/metabolism , Chemotaxis, Leukocyte , Animals , Cell Movement , Chemokine CCL2/metabolism , Chemokine CXCL1/metabolism , Joints/pathology , Mice , Microscopy, Confocal/methods , Neutrophils/metabolism , Neutrophils/pathology , Pleural Cavity/metabolism , Pleural Cavity/pathology , Receptors, CCR2/metabolism , Receptors, Interleukin-8B/administration & dosage , Receptors, Interleukin-8B/metabolismABSTRACT
Acrocomia aculeata, popularly known as "bocaiuva," is widely acknowledged in culinary and traditional medicines to treat cardiovascular diseases, a combined effect with diuretics that are also used for hypertension. However, there are no scientific data published to support its use as functional food and its ethnopharmacological use. This study intended to determine the composition of fatty acids of the pulp oil and evaluate the diuretic action and anti-inflammatory activity of the in natura and microencapsulated oil orally administrated on rats. The obtained results confirm the prevalence of monounsaturated fatty acids (68.51%), especially oleic acid (65.68%±1.05%), in the oil from the bocaiuva pulp. The in natura A. aculeata oil has diuretic (P<.01) and anti-inflammatory potential, which promoted a marked inhibition on the hind paw edema induced by carrageenan (67%±7% after 2 h) (P<.01). In addition, results show that the oral administration of the bocaiuva oil at 300 (P<.05) and 700 (P<.05) mg/kg doses significantly inhibited the leukocyte migration induced by carrageenan to the pleural cavity in rats. The inhibitions equaled 91%±3% and 81%±16%, respectively. The microencapsulated oil also showed antiedematogenic (P<.01) as well as diuretic activities (P<.01). The microencapsulation by complex coacervation was shown to be a technique that favors the bioavailability and preservation of bioactive components of the bocaiuva oil.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Arecaceae/chemistry , Diuretics/pharmacology , Inflammation/drug therapy , Oleic Acid/therapeutic use , Phytotherapy , Plant Oils/therapeutic use , Animals , Anti-Inflammatory Agents/analysis , Anti-Inflammatory Agents/pharmacology , Antihypertensive Agents/analysis , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Carrageenan , Cell Movement , Diuretics/analysis , Drug Compounding , Edema/chemically induced , Edema/drug therapy , Edema/metabolism , Fruit/chemistry , Inflammation/chemically induced , Inflammation/metabolism , Leukocytes/metabolism , Male , Oleic Acid/analysis , Oleic Acid/pharmacology , Plant Oils/chemistry , Plant Oils/pharmacology , Pleural Cavity/metabolism , Rats, Wistar , Urination/drug effectsABSTRACT
Several emerging lines of evidence support an anti-inflammatory role for nicotinic acid (niacin); however, its role in the regulation of leukocyte migration in response to inflammatory stimuli has not been elucidated until now. Herein, we have examined the effect of nicotinic acid on neutrophil recruitment in experimentally induced inflammation. We demonstrated that nicotinic acid treatment inhibited interleukin (IL)-8-induced, leukotriene (LT)B4-induced, and carrageenan-induced neutrophil migration into the pleural cavity of BALB/c mice and reduced neutrophil rolling and adherence in a mouse cremaster muscle preparation. Surprisingly, nicotinic acid treatment increased the level of the neutrophil chemoattractant KC in response to carrageenan. These results suggest that nicotinic acid plays an important role in the regulation of inflammation due to its ability to inhibit the actions of the neutrophil chemoattractants IL-8 and LTB4. Further inhibition of chemoattractants leads to impairment of leukocyte rolling and adherence to the vascular endothelium in the microcirculation of inflamed tissues.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Immune System Diseases/prevention & control , Inflammation/drug therapy , Leukocyte Disorders/prevention & control , Niacin/pharmacology , Animals , Carrageenan/pharmacology , Cell Adhesion/drug effects , Chemokine CXCL1/metabolism , Disease Models, Animal , Inflammation/pathology , Interleukin-8/pharmacology , Leukocyte Rolling/drug effects , Leukotriene B4/pharmacology , Male , Mice , Mice, Inbred BALB C , Neutrophil Infiltration/drug effects , Pleural Cavity/drug effects , Pleural Cavity/metabolismABSTRACT
OBJECTIVE AND DESIGN: Although proteinase-activated receptor (PAR)-4 has been implicated in inflammation, its role in regulating eosinophil recruitment in response to chemoattractants has not yet been demonstrated. To investigate the contribution of proteinases and PAR-4 activation to eosinophil migration in response to eotaxin-1 or leukotriene B(4) (LTB(4)), the effects of aprotinin or PAR-4 antagonist trans-cinnamoyl-YPGKF-NH(2) (tcY-NH(2)) on eosinophil migration induced by these chemoattractants were investigated. METHODS: BALB/c mice were pretreated with aprotinin or tcY-NH(2) (30 µg/mouse) prior to intrapleural injection of LTB(4) or eotaxin-1 and the number of infiltrating eosinophils was determined 48 h later. RESULTS: Aprotinin (1 mg/kg) inhibited eosinophil recruitment induced by eotaxin-1 (p < 0.01), but not that induced by LTB(4). Moreover, tcY-NH(2) treatment inhibited eosinophil recruitment in response to eotaxin-1 (p < 0.01 by ANOVA/Tukey post-test). CONCLUSION: These data suggest that aprotinin-inhibited proteinases participate in eosinophil migration induced by eotaxin-1 and that PAR-4 activation plays an important role in regulating this migration.
Subject(s)
Aprotinin/pharmacology , Chemokine CCL11/pharmacology , Eosinophils/drug effects , Receptors, Proteinase-Activated/metabolism , Animals , Cell Movement , Cinnamates/pharmacology , Eosinophils/metabolism , Leukotriene B4/pharmacology , Male , Mice , Mice, Inbred BALB C , Oligopeptides/pharmacology , Ovalbumin/immunology , Pleural Cavity/drug effects , Pleural Cavity/immunology , Pleural Cavity/metabolism , Pleurisy/immunologyABSTRACT
PURPOSE: To determine serum and pleural concentrations of tumor necrosis factor alpha (TNF-α) in an experimental model of empyema induced by intrapleural inoculation of Staphylococcus aureus or Streptococcus pneumoniae. METHODS: Wistar rats were inoculated with S. aureus (SA group, 17 animals) or S. pneumoniae (SP group, 30 animals). The presence of free fluid or pus in the pleural space was investigated. TNF-α levels >150 pg/ml (minimum detection limit) were determined in pleural fluid and blood. Histopathological examination of pleural tissue was performed to determine the severity of infection. RESULTS: Serum TNF-α was >150 pg/ml in nine SA versus 10 SP rats. In pleural fluid, TNF-α was >150 pg/ml in 11 SA versus 19 SP rats. Pleural and serum TNF-α concentrations were significantly different in the SP group (P = 0.035), but not in the SA group (P = 0.727). Pleural TNF-α was similar in both groups (P = 0.92), but serum TNF-α was significantly higher in SA (P = 0.03). Out of 17 SA animals, 1 (5.8%) did not develop empyema, versus 4 (13.3%) out of 30 SP animals. A mild inflammatory response was predominant in both groups, but the inflammatory process was significantly more severe in SP (P = 0.012). However, TNF-α levels were not associated with severity of the inflammatory response. CONCLUSIONS: We describe a simple and effective rat model of empyema. TNF-α levels above 150 pg/ml in the pleural fluid are useful to confirm empyema, but cannot predict the severity of the inflammatory response. TNF-α levels below 150 pg/ml are useful to rule out empyema.
Subject(s)
Empyema, Pleural/metabolism , Pleural Cavity/metabolism , Tumor Necrosis Factor-alpha/metabolism , Animals , Disease Models, Animal , Empyema, Pleural/diagnosis , Pleural Cavity/microbiology , Predictive Value of Tests , Rats , Rats, Wistar , Sensitivity and Specificity , Severity of Illness IndexABSTRACT
BACKGROUND: The addition of a nitric oxide (NO)-releasing moiety to prednisolone was shown to enhance the anti-inflammatory activity of this glucocorticoid in some experimental conditions, but its effectiveness in the context of eosinophilic inflammation remains to be elucidated. OBJECTIVE: This study compared the anti-inflammatory effect of prednisolone to a NO-releasing derivative of prednisolone, NCX-1015, using a model of allergen-evoked eosinophil recruitment in rats. The efficacy of a NO-donor compound, DETA-NONOate, was also assessed for comparison. METHODS: Wistar rats were actively sensitized with Al(OH)(3) plus ovalbumin and 14 days later challenged with antigen intrapleurally. Treatments were performed locally 1 h before challenge. Cysteinyl-leucotrienes (Cys-LT) and eotaxin were measured by ELISA. RESULTS: Antigen challenge induced an eosinophil infiltration at 12 h, maximal at 24 h. It also caused an increase in the levels of Cys-LTs in the pleural exudate and in the expression of 5-lipoxygenase (5-LO) in infiltrated leucocytes at 6 h, peaking at 12 h and persisting for at least 24 h. Treatment with equimolar doses of prednisolone and NCX-1015 inhibited the late eosinophil infiltration, although the dose required to produce maximal inhibition was about one-tenth that of prednisolone. Cys-LT generation and 5-LO expression were inhibited by NCX-1015 but not by prednisolone. Treatment with prednisolone combined with the NO-donor DETA-NONOate led to a greater inhibition of the eosinophilia and Cys-LT generation as compared with either drug alone. Administration of the steroid receptor antagonist RU 486, 1 h before prednisolone and NCX-1015, abolished the inhibitory effect of the former, under conditions where it only partially affected the latter. CONCLUSIONS: Our findings indicate that NCX-1015 provided a greater anti-inflammatory effect than prednisolone on the allergic eosinophil recruitment in rats, suggesting that NO-releasing steroids can be considered as a promising therapeutic approach to allergic diseases.
Subject(s)
Eosinophilia/prevention & control , Hypersensitivity/complications , Nitric Oxide Donors/therapeutic use , Pleurisy/prevention & control , Prednisolone/analogs & derivatives , Animals , Anti-Inflammatory Agents/therapeutic use , Arachidonate 5-Lipoxygenase/metabolism , Chemokine CCL11/metabolism , Cysteine/metabolism , Disease Models, Animal , Drug Therapy, Combination , Eosinophilia/etiology , Eosinophilia/pathology , Eosinophils/cytology , Hypersensitivity/drug therapy , Leukocytes/cytology , Leukocytes/metabolism , Leukocytes, Mononuclear/cytology , Leukotrienes/metabolism , Male , Mifepristone/pharmacology , Neutrophils/cytology , Nitroso Compounds/therapeutic use , Ovalbumin/immunology , Pleural Cavity/metabolism , Pleural Cavity/pathology , Pleurisy/etiology , Pleurisy/pathology , Prednisolone/therapeutic use , Rats , Rats, Wistar , Receptors, Glucocorticoid/antagonists & inhibitorsABSTRACT
This study was undertaken to investigate the role of the aldose reductase in the refractoriness of diabetic rats to allergic inflammation. Wistar rats were actively sensitized with a mixture of Al(OH)3 plus ovalbumin and intrapleurally challenged with ovalbumin, 14 days later. Diabetes was induced by intravenous injection of alloxan into fasted rats, 7 days before sensitization, and the aldose reductase inhibitor zopolrestat was administered after 3 days of diabetes induction, once a day during 18 consecutive days. The treatment with zopolrestat restored antigen-induced protein extravazation and mast cell degranulation in the pleural cavity of diabetic sensitized rats. Zopolrestat also significantly reversed the suppression in the increase of total and specific levels of serum immunoglobulin E (IgE) noted in sensitized animals under conditions of diabetes. In addition, we noted that the drop in the pleural mast cell numbers as well as the increase in serum corticosterone levels in diabetic rats were inhibited by the drug. Our findings show that zopolrestat restored the hyporesponsiveness of diabetic rats to antigen provocation, in parallel with impairment of alloxan-induced mast cell depletion and hypercorticolism, indicating that polyol pathway activity seems to play an important role in these phenomena.
Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Benzothiazoles/pharmacology , Diabetes Mellitus, Experimental/physiopathology , Hypersensitivity/physiopathology , Phthalazines/pharmacology , Aldehyde Reductase/metabolism , Alloxan , Aluminum Hydroxide/immunology , Animals , Cell Count , Cell Degranulation/drug effects , Corticosterone/blood , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/chemically induced , Hypersensitivity/immunology , Hypersensitivity/prevention & control , Hypoglycemic Agents/pharmacology , Immunoglobulin G/blood , Insulin/blood , Male , Mast Cells/cytology , Mast Cells/drug effects , Mast Cells/physiology , Ovalbumin/immunology , Pleural Cavity/cytology , Pleural Cavity/drug effects , Pleural Cavity/metabolism , Proteins/metabolism , Rats , Rats, WistarABSTRACT
OBJECTIVES: In the present study we assessed the inflammatory potential of venom obtained from caterpillar genus Dirphia in an acute model of lung injury. MATERIAL AND METHODS: Injection of extract from the bristles of Dirphia sp. (EBD) into the pleural cavity of rats elicited an acute inflammation response characterized by fluid accumulation which contained a large number of polymorphonuclear neutrophils (PMNs). RESULTS: The results show that EBD induces an inflammatory response, with a significant increase in PMNs, exudate and nitric oxide within 4 h after a 0.04 mg/kg dose. The administration of anti-inflammatory drugs (fructose-1,6-bisphosphate, dexamethasone, rofecoxib, sodium diclofenac and pyrilamine) significantly reduced the inflammatory effect of EBD. CONCLUSIONS: EBD causes an inflammatory reaction in the pleural cavity of rats involving a variety of inflammatory mediators, its action mechanism probably involving cellular injury and the exacerbated induction of cytokines and nitric oxide.